NeuMoDx Molecular Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 175

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $248M

NeuMoDx Molecular General Information

Description

Operator of a healthcare technology platform intended to offer molecular diagnostic testing tools. The company's platform offers in-vitro molecule testing facilities in hospitals and clinical reference laboratories, enabling laboratory professionals to operate more efficiently and cost-effectively, and increasing the use of molecular diagnostic testing by medical providers to better identify and treat disease early.

Contact Information

Website
www.neumodx.com
Formerly Known As
Molecular Systems, Molecular Systems Corp
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1250 Eisenhower Place
  • Ann Arbor, MI 48108
  • United States
+1 (734)
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Technology Systems
Acquirer
Vertical(s)
Corporate Office
  • 1250 Eisenhower Place
  • Ann Arbor, MI 48108
  • United States
+1 (734)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuMoDx Molecular Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Merger/Acquisition 17-Sep-2020 $248M Completed Generating Revenue
10. Debt - General 31-Dec-2019 Completed Generating Revenue
9. Debt - General 30-Sep-2019 Completed Generating Revenue
8. Debt - General 01-Apr-2019 Completed Generating Revenue
7. Debt - General 30-Sep-2018 Completed Generating Revenue
6. Later Stage VC 27-Apr-2018 Completed Generating Revenue
5. Later Stage VC 01-Jan-2018 Completed Generating Revenue
4. Early Stage VC 29-Apr-2016 Completed Startup
3. Early Stage VC (Series B) 16-Jun-2015 $26.1M Completed Startup
2. Early Stage VC (Series B) 01-Apr-2014 $21.1M $26.1M Completed Startup
To view NeuMoDx Molecular’s complete valuation and funding history, request access »

NeuMoDx Molecular Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series Q1
Series Q
Series B 5,936,420 $0.000100 8% $3.55 $3.55 1x $3.55 34.5%
Series A 3,202,869 $0.000100 8% $1.56 $1.56 1x $1.56 18.61%
To view NeuMoDx Molecular’s complete cap table history, request access »

NeuMoDx Molecular Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a healthcare technology platform intended to offer molecular diagnostic testing tools. The company's platfor
Diagnostic Equipment
Ann Arbor, MI
175 As of 2020

Newcastle Upon Tyne, United Kingdom
 

Toronto, Canada
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NeuMoDx Molecular Competitors (48)

One of NeuMoDx Molecular’s 48 competitors is QuantuMDx, a Venture Capital-Backed company based in Newcastle Upon Tyne, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
QuantuMDx Venture Capital-Backed Newcastle Upon Tyne, United Kingdom
ChipCare Formerly VC-backed Toronto, Canada
Q-linea Formerly VC-backed Uppsala, Sweden
Rheonix Venture Capital-Backed Ithaca, NY
Biocartis Venture Capital-Backed Mechelen, Belgium
You’re viewing 5 of 48 competitors. Get the full list »

NeuMoDx Molecular Patents

NeuMoDx Molecular Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3122903-A1 System and method for processing biological samples Active 28-Mar-2014
EP-3122903-A4 System and method for processing biological samples Active 28-Mar-2014
WO-2015149057-A1 System and method for processing biological samples Inactive 28-Mar-2014
ES-2805541-T3 System and procedure for processing biological samples Active 28-Mar-2014
EP-3122903-B1 System for processing biological samples Inactive 28-Mar-2014 C12Q1/6806
To view NeuMoDx Molecular’s complete patent history, request access »

NeuMoDx Molecular Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeuMoDx Molecular Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
Arboretum Ventures Venture Capital Minority
Baird Capital PE/Buyout Minority
Clarevia Ventures Venture Capital Minority
Pfizer Ventures Corporate Venture Capital Minority
University of Michigan Endowment Limited Partner Minority
To view NeuMoDx Molecular’s complete investors history, request access »

NeuMoDx Molecular FAQs

  • When was NeuMoDx Molecular founded?

    NeuMoDx Molecular was founded in 2012.

  • Where is NeuMoDx Molecular headquartered?

    NeuMoDx Molecular is headquartered in Ann Arbor, MI.

  • What is the size of NeuMoDx Molecular?

    NeuMoDx Molecular has 175 total employees.

  • What industry is NeuMoDx Molecular in?

    NeuMoDx Molecular’s primary industry is Diagnostic Equipment.

  • Is NeuMoDx Molecular a private or public company?

    NeuMoDx Molecular is a Private company.

  • What is the current valuation of NeuMoDx Molecular?

    The current valuation of NeuMoDx Molecular is .

  • What is NeuMoDx Molecular’s current revenue?

    The current revenue for NeuMoDx Molecular is .

  • How much funding has NeuMoDx Molecular raised over time?

    NeuMoDx Molecular has raised $85.6M.

  • Who are NeuMoDx Molecular’s investors?

    Arboretum Ventures, Baird Capital, Clarevia Ventures, Pfizer Ventures, and University of Michigan Endowment have invested in NeuMoDx Molecular.

  • Who are NeuMoDx Molecular’s competitors?

    QuantuMDx, ChipCare, Q-linea, Rheonix, and Biocartis are some of the 48 competitors of NeuMoDx Molecular.

  • When was NeuMoDx Molecular acquired?

    NeuMoDx Molecular was acquired on 17-Sep-2020.

  • Who acquired NeuMoDx Molecular?

    NeuMoDx Molecular was acquired by Qiagen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process